OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

H. C. Diener, D. W. Dodick, S. K. Aurora, C. C. Turkel, R. E. Degryse, Richard B. Lipton, S. D. Silberstein, M. F. Brin

Research output: Contribution to journalArticle

476 Citations (Scopus)

Abstract

Objectives: This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic migraine. Methods: PREEMPT 2 was a phase 3 study, with a 24-week, double-blind, placebo-controlled phase, followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections of onabotulinumtoxinA (155U-195U; n = 347) or placebo (n = 358) every 12 weeks for two cycles. The primary efficacy endpoint was mean change in headache days per 28 days from baseline to weeks 21-24 post-treatment. Results: OnabotulinumtoxinA was statistically significantly superior to placebo for the primary endpoint, frequency of headache days per 28 days relative to baseline (-9.0 onabotulinumtoxinA/-6.7 placebo, p <.001). OnabotulinumtoxinA was significantly favoured in all secondary endpoint comparisons. OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few patients (3.5% onabotulinumtoxinA/1.4% placebo) discontinued due to adverse events. Conclusions: The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine. Repeated onabotulinumtoxinA treatments were safe and well tolerated.

Original languageEnglish (US)
Pages (from-to)804-814
Number of pages11
JournalCephalalgia
Volume30
Issue number7
DOIs
StatePublished - Jul 2010

Fingerprint

Migraine Disorders
Placebos
Headache
Therapeutics
onabotulinumtoxinA
Safety
Injections

Keywords

  • botulinum toxin A
  • chronic migraine
  • prophylaxis

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

OnabotulinumtoxinA for treatment of chronic migraine : Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. / Diener, H. C.; Dodick, D. W.; Aurora, S. K.; Turkel, C. C.; Degryse, R. E.; Lipton, Richard B.; Silberstein, S. D.; Brin, M. F.

In: Cephalalgia, Vol. 30, No. 7, 07.2010, p. 804-814.

Research output: Contribution to journalArticle

Diener, H. C. ; Dodick, D. W. ; Aurora, S. K. ; Turkel, C. C. ; Degryse, R. E. ; Lipton, Richard B. ; Silberstein, S. D. ; Brin, M. F. / OnabotulinumtoxinA for treatment of chronic migraine : Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. In: Cephalalgia. 2010 ; Vol. 30, No. 7. pp. 804-814.
@article{02905551499142b696b977563fe1d271,
title = "OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial",
abstract = "Objectives: This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX{\circledR}) for prophylaxis of headaches in adults with chronic migraine. Methods: PREEMPT 2 was a phase 3 study, with a 24-week, double-blind, placebo-controlled phase, followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections of onabotulinumtoxinA (155U-195U; n = 347) or placebo (n = 358) every 12 weeks for two cycles. The primary efficacy endpoint was mean change in headache days per 28 days from baseline to weeks 21-24 post-treatment. Results: OnabotulinumtoxinA was statistically significantly superior to placebo for the primary endpoint, frequency of headache days per 28 days relative to baseline (-9.0 onabotulinumtoxinA/-6.7 placebo, p <.001). OnabotulinumtoxinA was significantly favoured in all secondary endpoint comparisons. OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few patients (3.5{\%} onabotulinumtoxinA/1.4{\%} placebo) discontinued due to adverse events. Conclusions: The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine. Repeated onabotulinumtoxinA treatments were safe and well tolerated.",
keywords = "botulinum toxin A, chronic migraine, prophylaxis",
author = "Diener, {H. C.} and Dodick, {D. W.} and Aurora, {S. K.} and Turkel, {C. C.} and Degryse, {R. E.} and Lipton, {Richard B.} and Silberstein, {S. D.} and Brin, {M. F.}",
year = "2010",
month = "7",
doi = "10.1177/0333102410364677",
language = "English (US)",
volume = "30",
pages = "804--814",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - OnabotulinumtoxinA for treatment of chronic migraine

T2 - Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

AU - Diener, H. C.

AU - Dodick, D. W.

AU - Aurora, S. K.

AU - Turkel, C. C.

AU - Degryse, R. E.

AU - Lipton, Richard B.

AU - Silberstein, S. D.

AU - Brin, M. F.

PY - 2010/7

Y1 - 2010/7

N2 - Objectives: This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic migraine. Methods: PREEMPT 2 was a phase 3 study, with a 24-week, double-blind, placebo-controlled phase, followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections of onabotulinumtoxinA (155U-195U; n = 347) or placebo (n = 358) every 12 weeks for two cycles. The primary efficacy endpoint was mean change in headache days per 28 days from baseline to weeks 21-24 post-treatment. Results: OnabotulinumtoxinA was statistically significantly superior to placebo for the primary endpoint, frequency of headache days per 28 days relative to baseline (-9.0 onabotulinumtoxinA/-6.7 placebo, p <.001). OnabotulinumtoxinA was significantly favoured in all secondary endpoint comparisons. OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few patients (3.5% onabotulinumtoxinA/1.4% placebo) discontinued due to adverse events. Conclusions: The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine. Repeated onabotulinumtoxinA treatments were safe and well tolerated.

AB - Objectives: This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic migraine. Methods: PREEMPT 2 was a phase 3 study, with a 24-week, double-blind, placebo-controlled phase, followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections of onabotulinumtoxinA (155U-195U; n = 347) or placebo (n = 358) every 12 weeks for two cycles. The primary efficacy endpoint was mean change in headache days per 28 days from baseline to weeks 21-24 post-treatment. Results: OnabotulinumtoxinA was statistically significantly superior to placebo for the primary endpoint, frequency of headache days per 28 days relative to baseline (-9.0 onabotulinumtoxinA/-6.7 placebo, p <.001). OnabotulinumtoxinA was significantly favoured in all secondary endpoint comparisons. OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few patients (3.5% onabotulinumtoxinA/1.4% placebo) discontinued due to adverse events. Conclusions: The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine. Repeated onabotulinumtoxinA treatments were safe and well tolerated.

KW - botulinum toxin A

KW - chronic migraine

KW - prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=77953223552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953223552&partnerID=8YFLogxK

U2 - 10.1177/0333102410364677

DO - 10.1177/0333102410364677

M3 - Article

C2 - 20647171

AN - SCOPUS:77953223552

VL - 30

SP - 804

EP - 814

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 7

ER -